Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-CAR T: AZD0120 in Relapsed and Refractory Persistent Autoimmune Cytopenia
NCT07790575Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Jul 2041
- Countries
- 1
01
Overview
Phase 1, open-label trial of GC012 in immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) (2 arms). Primary endpoint: Incidence of adverse events at 28 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
GC012
03
Conditions
immune thrombocytopenia (ITP)autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07790575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790575.